---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113623"
form_type: "8-K"
ticker: "ISPC"
cik: "0001558569"
company_name: "iSpecimen Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:11:35.433114+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iSpecimen Q3 revenue $2.8M (+8% YoY, +75% sequential); net loss $2.1M; cash burn persists

## Summary
- Revenue of $2.8M for Q3 2023 vs $2.6M in Q3 2022; sequential growth of 75% from $1.6M in Q2 2023.
- Net loss of $2.1M ($0.23 per share) improved from $3.1M loss ($0.35) in Q3 2022; 9-month loss $8.0M ($0.89).
- Cash and securities totaled $5.6M as of Sept 30, 2023, down from $15.3M at Dec 31, 2022; cash burn $9.7M in 9M2023.
- Unique customer organizations reached 603 (+26% YoY); registered users 7,326 (+15% YoY); supplier orgs 234.
- CEO targets cash flow neutral by year end; launched Next-Day Quote and Cancer Sequencing Procurement Program.

## SEC filing metadata
- accession: 0001104659-23-113623
- form_type: 8-K
- ticker: ISPC
- cik: 0001558569
- company_name: iSpecimen Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/0001104659-23-113623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/tm2329606d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113623
- JSON: https://secwatch.observer/filing/0001104659-23-113623.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113623.txt

## Key facts
- Earnings Releases
  iSpecimen Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $2.8 million for the three-month period ended September 30, 2023, net income $2.1 million, or $(0.23) per share, EPS $(0.23) per share.
  - Period: the three and nine month periods ended September 30, 2023
  - Revenue: $2.8 million for the three-month period ended September 30, 2023
  - Net income: $2.1 million, or $(0.23) per share
  - EPS: $(0.23) per share
  - Result: reported results
  source text: iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1558569/000110465923113623/0001104659-23-113623-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.